Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 1982 Nov 15;144(6):630-5
Date
11/15/1982Pubmed ID
7137247DOI
10.1016/0002-9378(82)90430-6Scopus ID
2-s2.0-0020454832 (requires institutional sign-in at Scopus site) 77 CitationsAbstract
To study the association of the use of oral contraceptives and pelvic inflammatory disease (PID), we analyzed data from a large multicenter case-control study of contraceptive use and serious gynecologic disorders. The analysis included data from interviews of 648 women hospitalized with an initial episode of PID and 2,516 hospitalized control subjects. The risk of PID for women using oral contraceptives in the 3 months prior to interview was 0.5 (95% confidence limits, 0.4 to 0.6) relative to women using no contraceptive method during this period. This association was not explained by differences between case subjects and control subjects in demographic variables, level of sexual activity, or medical history. The protective effect of current oral contraceptive use against PID was restricted to women using oral contraceptives for more than 12 months; past use of oral contraceptives did not exert a protective effect against PID. Annually, an estimated 50,000 initial cases of PID are prevented by oral contraceptive use; 12,500 hospitalizations are also averted by oral contraceptive use. Consequently, protection against PID is one of the most important noncontraceptive benefits of oral contraception.
Author List
Rubin GL, Ory HW, Layde PMAuthor
Peter M. Layde MS, MD Emeritus Professor in the Emergency Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Contraceptives, Oral
Female
Humans
Pelvic Inflammatory Disease
Risk
Time Factors
